AI Meets Aging Research: First Epigenetic Age Reversal Drug Candidate Nears Human Trials

Harvard's David Sinclair previews ER-100, an epigenetic age reversal drug candidate heading toward human trials, alongside a new paper on using AI and eye imaging as a biomarker for health span.

David Sinclair, the Harvard longevity researcher, shared a new collaborative review paper on "Oculomics and AI: The eye as a biomarker for health span," published in anticipation of ER-100 — described as "the first epigenetic age reversal drug candidate" — going into human trials, as @davidasinclair announced.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae.

Unlock the full briefing

Get every story in today's briefing, the full archive, and the daily AI intelligence brief.

All stories today

Full archive

Daily brief